Abstract
Ciclosporin (CyA) is a potent immunosuppressive agent which acts selectively upon the immune response by inhibition of the lymphokine cascade, thus inhibiting cell-cell communication [1]. In addition, augmentation of the inflammatory response is attenuated by blockade of macrophage migration inhibition factor (MIF) and macrophage arming factor (MAF), limiting the delayed-type hypersensitivity response and immunologically nonspecific tissue injury [2]. By virtue of its efficacy and immunologic specificity, CyA is employed extensively in organ transplantation, and also appears to be of major potential importance in the area of auto-immunity.
Supported in part by grants from the Medical Research Council of Canada, the Ivey Foundation, and the Kidney Foundation of Canada
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bunjes, Hardic D, Rollinghoff M, Wagner H (1981) Cyclosporin A Mediates Immunosuppression of Primary Cytotoxic T-Cell Responses by Impairing the Release of Interleukin 1 and Interleukin 2. Eur J Immunol 11:657–661
Thompson AW, Moon DK, Geczy CL, Nelson DS (1983) Cyclosporin A Inhibits Lymphokine Production but not the Responses of Macrophages to Lymphokines. Immunology 48:291–299
Beveridge T, Gratwohl A, Michot F et al. (1981) Cyclosporin A: Pharmacokinetics after a Single Dose in Man and Serum Levels after Multiple Dosing in Recipients of Allogeneic Bone-Marrow Grafts. Current Therapeutic Research 30:5–18
Keown PA, Stiller CR, Ulan RA et al. (1981) Immunological and Pharmacological Monitoring in the Clinical Use of Cyclosporin A. Lancet 1:686–689
Lemaire M, Tillement JP (1982) Role of Lipoproteins and Erythrocytes in the In Vitro Binding and Distribution of Cyclosporin A in the Blood. J Pharm Pharmacol 34:715–718
Wall WJ, Keown PA, Stiller CR, McKenzie N, Devinini R, Stawecki M, McMichael J, Howson W, Muirhead N, Hollomby D (1984) Efficacy and Safety of Low Dose Continuous Intravenous Cyclosporine (CyA). Abstracts: 10th International Congress of The Transplantation Society, Minneapolis S 3.6, 61–62
Keown PA, Laupacis A, Carruthers G, Stawecki M, Koegler J, McKenzie FN, Wall W, Stiller CR (1984) Interaction between Phenytoin and Cyclosporine following Organ Transplantation. Transplantation, Vol 38, No 3, 304–306
Ferguson RM, Sutherland DE, Simmons RL, Najarian JS (1982) Ketoconazole, Cyclosporin Metabolism, and Renal Transplantation ( Letter ). Lancet 2:882–3
Keown PA (1984) Cyclosporine Blood Level Monitoring. Transplantation Immunology Letter Supplement, Vol 1, No 2, November
Keown PA, Stiller CR, Laupacis AL et al. (1982) The Effects and Side-effects of Cyclosporine: Relationship to Drug Pharmacokinetics. Transplantation Proceedings 14:659–661
Stiller CR, Dupre J, Gent M, Jenner MR, Keown PA, Laupacis A, Martell R, Rodger NW, Graffenried B, Wolfe BMJ (1984) Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset. Science 223:1362–1367
Petric R, Keown PA, Stiller CR, Wallace AC, McDonald JWD (1985) Affect of Cyclosporine (CyA) on Renal Function, Blood Flow, and Prostacyclin A and Thromboxane Generation in Experimental Animal Model. 1st International Meeting on Experimental Cyclosporine Nephrotoxicity, Basel, April (Abstract)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Sandoz Ltd, Basle
About this paper
Cite this paper
Keown, P.A., Stiller, C.R., Stawecki, M., McMichael, J., Howson, W. (1985). Pharmacokinetics and Interactions of Ciclosporin. In: Schindler, R. (eds) Ciclosporin in Autoimmune Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70607-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-70607-3_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-70609-7
Online ISBN: 978-3-642-70607-3
eBook Packages: Springer Book Archive